World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
51
Citations
15710
World Ranking
4109
National Ranking
362

Overview

John Frater is affiliated with the University of Oxford in the United Kingdom. Their research primarily focuses on medicine, with significant contributions in immunology and microbiology. The subfields they work in include infectious diseases, immunology, virology, molecular biology, and epidemiology.

Their main research topics encompass HIV research and treatment, SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, HIV/AIDS research and interventions, HIV/AIDS drug development and treatment, immune cell function and interaction, and vaccines and immunoinformatics approaches.

Recent papers authored or co-authored by John Frater include:

  • Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 (2020, Nature Immunology)
  • SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2022, Cell)
  • Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum (2022, Cell)
  • Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison (2020, The Lancet Infectious Diseases)
  • Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine (2021, Cell)

Frequent co-authors who have collaborated extensively with John Frater include:

  • Paul Klenerman (35 publications)
  • Sarah Fidler (35 publications)
  • Susanna Dunachie (33 publications)
  • Eleanor Barnes (33 publications)
  • Philip Goulder (26 publications)

John Frater publishes regularly in several notable venues. The most frequent publication venues are:

  • bioRxiv (Cold Spring Harbor Laboratory) - 8 publications
  • SSRN Electronic Journal - 7 publications
  • Nature Communications - 6 publications
  • Frontiers in Immunology - 6 publications
  • Journal of Virus Eradication - 6 publications

Best Publications

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

    M Voysey;Clemens Sac.;S A Madhi;L Y Weckx

  • SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

    Unknown

  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

    M Voysey;S A Costa Clemens;S A Madhi;L Y Weckx

  • Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.

    Y Peng;A J Mentzer;G Liu;G Liu;X Yao

  • CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

    Photini Kiepiela;Kholiswa Ngumbela;Christina Thobakgale;Dhanwanthie Ramduth

  • Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

    Unknown

  • HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

    Ravindra K. Gupta;Sultan Abdul-Jawad;Laura E. McCoy;Hoi Ping Mok

  • T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

    K J Ewer;Barrett;S Belij-Rammerstorfer;H Sharpe

  • Adaptation of HIV-1 to human leukocyte antigen class I

    Y. Kawashima;K. Pfafferott;J. Frater;P. Matthews

  • A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

    Unknown

  • Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

    M Ainsworth;M Andersson;M Andersson;K Auckland;J K Baillie

  • Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.

    Cormac Cosgrove;James E. Ussher;Andri Rauch;Kathleen Gärtner

  • HIV-1 DNA predicts disease progression and post-treatment virological control

    James P Williams;Jacob Hurst;Jacob Hurst;Wolfgang Stöhr;Nicola Robinson;Nicola Robinson

  • Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

    R P Payne;S Longet;J A Austin;D T Skelly

  • Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

    Barrett;S Belij-Rammerstorfer;C Dold;K J Ewer

  • Selection bias at the heterosexual HIV-1 transmission bottleneck

    Jonathan M. Carlson;Malinda Schaefer;Daniela C. Monaco;Rebecca Batorsky

  • Short-course antiretroviral therapy in primary HIV infection.

    S Fidler;K Porter;F Ewings

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

    J Frater;K J Ewer;A Ogbe;M Pace

  • Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

    Ravindra Kumar Gupta;Dimitra Peppa;Dimitra Peppa;Alison L Hill;Cristina Gálvez

  • Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans.

    Kathleen B. Yates;Kathleen B. Yates;Pierre Tonnerre;Pierre Tonnerre;Genevieve E. Martin;Genevieve E. Martin;Ulrike Gerdemann

  • The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses

    Unknown

  • Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

    Boris Julg;Boris Julg;Lynda Dee;Jintanat Ananworanich;Dan H Barouch;Dan H Barouch

  • Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

    Jacob Hurst;Matthias Hoffmann;Matthew Pace;Matthew Pace;James P. Williams

  • Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, ‘definetherain’

    Mathew Jones;James Williams;Kathleen Gärtner;Rodney Phillips

  • Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

    D T Skelly;A C Harding;J Gilbert-Jaramillo;M L Knight

  • Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.

    Matthias Hoffmann;Matthias Hoffmann;Nikos Pantazis;Genevieve E. Martin;Stephen Hickling

  • Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (preprint)

    Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A.;Weckx, Lily Yin, Folegatti, Pedro M.;Parvinder K. Aley;Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L.

Frequent Co-Authors

Sarah Fidler
Sarah Fidler Imperial College London
Philip J. R. Goulder
Philip J. R. Goulder University of Oxford
Paul Klenerman
Paul Klenerman University of Oxford
Rodney E. Phillips
Rodney E. Phillips University of Oxford
Bruce D. Walker
Bruce D. Walker Harvard University
Thumbi Ndung'u
Thumbi Ndung'u University of KwaZulu-Natal
Julie Fox
Julie Fox Guy's and St Thomas' NHS Foundation Trust
Susanna Dunachie
Susanna Dunachie University of Oxford
Philippa C. Matthews
Philippa C. Matthews University of Oxford
Eleanor Barnes
Eleanor Barnes University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, expanding knowledge through related healthcare degrees can open diverse career pathways. Many students pursue accelerated nursing programs to quickly transition into clinical roles. For example, an accelerated FNP program equips students with advanced skills in family nurse practice, blending immunological knowledge with patient care.

Non-nurses looking to enter the field might explore online ABSN programs for non nurses. These programs offer a streamlined pathway to becoming registered nurses, allowing students to build foundational clinical expertise relevant to immunology and other specialties.

Many institutions also provide options that are accessible and less competitive, such as the easiest ABSN programs to get into, which can be ideal for candidates seeking flexible entry points without compromising quality education.

For those interested in practical nursing roles, LPN programs easy to get into offer a quicker route into healthcare support positions. These pathways allow for hands-on experience with immunological processes in various care settings, supporting long-term career growth.

Best Scientists Citing John Frater

Trending Scientists